THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

April 28, 2019
Daewoong's Nabota receives positive CHMP opinion

Daewoong Pharmaceutical‘s botulinum toxin Nabota received a positive opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), on April 26. The CHMP opinion is a scientific recommendation for marketing authorization to the European Commission, which will no...
April 24, 2019
L&K Biomed at risk of being delisted by KRX

L&K Biomed is at risk of being delisted by bourse operator Korea Exchange, according to industry sources on April 24. The South Korean health care company’s stock trading has been suspended, as an external accounting auditor has issued a “disclaimer of opinion” on its internal accounting contro...
April 23, 2019
Boryung Pharmaceutical establishes new production facility in Yesan

South Korean pharmaceutical company Boryung Pharmaceutical announced on April 23 that it has established a new production facility in Yesan, South Chungcheong Province. The new site in Yesan, which started construction in March 2017, spans around 145,097 square meters. Boryung Pharmaceutical has...
April 23, 2019
OliPass plans to go public this year

South Korean bio company OliPass is preparing to go public by the end of the year, according to sources on April 23. Preparing to start the initial public offering process, the company has picked Mirae Asset Daewoo and Kium Securities as IPO managers. According to sources, OliPass will file for p...
April 22, 2019
MitoImmune Therapeutics secures funds worth W12b

South Korean bio startup MitoImmune Therapeutics announced on April 22 that it has closed its series A round after raising 12 billion won ($10.5 million). Four investors -- the state-run Korea Development Bank, KB Investment, BNH Investment and SL Investment -- participated in the investment round...
April 19, 2019
Kyung Nam Pharm seeks new owner

Kyung Nam Pharm , a local drug maker known for its vitamin supplement Lemona, has decided to receive letters of intent from April 22-24 to find a new owner. The company plans to pick a buyer for its newly issued shares to become the biggest stakeholder. The preferred bidder will be chosen around ...
April 18, 2019
GenBody’s proposed IPO plans this year suffer setback

South Korean bio startup GenBody, which originally was planning an initial public offering this year, has changed its schedule, according to industry sources on April 18. According to sources, the firm’s decision was mainly due to a decrease in its corporate value. Established in 2012, GenBody i...
April 18, 2019
SK Biopharma signs contract with US new drug developer

SK Biopharmaceuticals, a drug development unit of South Korea’s telecom-to-energy conglomerate SK Group , announced on April 18 that it has signed a contract with US-based biotech company twoXAR to co-develop a new drug for treating non-small cell lung cancer. Non-small cell lung cancer is the ...
April 18, 2019
Legal battle looms as approval for 1st for-profit hospital gets canceled

Attempts to open a for-profit hospital in South Korea have collapsed, portending a long-drawn legal battle between Jeju Self-Governing Province and a Chinese group that feels betrayed. The approval for Greenland International Hospital, which was poised to become the nation’s first for-profit medi...
April 17, 2019
KHDI hosts 2019 Bio Korea Forum

Korea Health Industry Development Institute announced on April 17 that it is hosting the Bio Korea International Convention from April 17-19. Session coordinators, including Bridge Bio CEO Lee Jung-kyu and Korea University and Hospital professor Lee Sang-hun, introduced topics that will be discuss...
April 16, 2019
NeoImmuneTech’s drug candidate obtains US FDA orphan drug designation

NeoImmuneTech, an immunotherapy drug development company, announced on April 16 that its drug candidate HyLeukin-7 has been designated an orphan drug by the US Food and Drug Administration. HyLeukin-7, which is an immunotherapeutic treatment designed to induce T cell proliferation and that helps t...
April 11, 2019
Celltrion’s Truxima gets sales approval in Canada

Celltrion announced on April 11 that it has obtained marketing authorization from Health Canada for Truxima, its biosimilar for treating non-Hodgkin’s lymphoma. Truxima references Roche’s Rituxan (rituximab), which currently posts around 250 billion won ($220 million) in annual sales on average...
April 10, 2019
Kolon shares fluctuate on Invossa suspension

The share price of beleaguered Kolon Group ’s bio affiliates fluctuated after it announced its decision to suspend sales of Kolon Life Science’s new osteoarthritis drug Invossa on April 1 following a mislabeling mishap. Immediately after the announcement, Kolon Life Science’s stock price tumb...
April 10, 2019
Celltrion’s Herzuma market share reaches 10% in Europe

An affiliate of South Korean biopharmaceutical firm Celltrion said Wednesday that the market share of its biosimilar Herzuma reached 10 percent in Europe during the fourth quarter of last year. Celltrion Healthcare, which handles Celltrion’s overseas business, said Herzuma’s market share reac...
April 09, 2019
[INTERVIEW] Sky Labs aims to launch CART in Europe this year

Korean health care startup Sky Labs aims to launch its Cardio Tracker, or CART, a ring-type wearable device that detects a patient’s heart rhythm 24/7 using internet of things technologies. “From the beginning, our goal was to penetrate Europe and the US. We will also launch the product in South...

11 12 13 14 15 16

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099